EUVIMEDEUVIMED entdecken
Übersichtsarbeit

CCL20-CCR6 signaling in tumor microenvironment: Functional roles, mechanisms, and immunotherapy targeting

Qi Liu, Mingyuan Song, Yan Wang, Ping Zhang, Hao Zhang

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2025-07 · 1880 (3) · 189341

DOI: 10.1016/j.bbcan.2025.189341 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2025-07. Verfasst von Qi Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: Tumor Microenvironment, Receptors, CCR6, Chemokine CCL20, Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 224 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemokine CC motif ligand 20 (CCL20) is a molecule with immunomodulatory properties that is involved in the regulation of diseases such as chronic inflammation, autoimmune diseases, and cancer. It operates by binding to its specific receptor, CC chemokine receptor type 6 (CCR6), and activating a complex intracellular signaling network. Building on its established role in inflammatory diseases, recent research has expanded our understanding of CCL20 to encompass its critical contributions to the tumor microenvironment (TME), highlighting its significance in cancer progression. Numerous studies have emphasized its prominent role in regulating immune responses. Consequently, Monoclonal antibodies against CCL20 and inhibitors of CCR6 have been successfully developed to block downstream signaling, making the CCL20-CCR6 axis a promising and critical target in the TME. This offers potential immunotherapeutic strategies for cancers. In this review, we summarize the biological consequences of CCL20-CCR6 mediated signaling, its role and mechanisms in the TME, and its potential applications. We suggest that the CCL20-CCR6 axis may be a novel biomarker for tumor diagnosis and prognosis, as well as a therapeutic target in various cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentReceptors, CCR6Chemokine CCL20NeoplasmsImmunotherapyHumansSignal TransductionAnimals

Stichwörter der Autor:innen

CCL20CCR6ChemokineImmunosuppressionImmunotherapyTumor microenvironment

Substanzen

Receptors, CCR6Chemokine CCL20CCR6 protein, humanCCL20 protein, human

Autor:innen und Institutionen

  • Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang, China.
  • Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
  • Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang, China. Electronic address: haozhang@cmu.edu.cn.

Zitieren

APA

Liu, Q., Song, M., Wang, Y., Zhang, P., & Zhang, H. (2025). CCL20-CCR6 signaling in tumor microenvironment: Functional roles, mechanisms, and immunotherapy targeting. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1880(3), 189341. https://doi.org/10.1016/j.bbcan.2025.189341

Vancouver

Liu Q, Song M, Wang Y, Zhang P, Zhang H. CCL20-CCR6 signaling in tumor microenvironment: Functional roles, mechanisms, and immunotherapy targeting. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2025;1880(3):189341. doi:10.1016/j.bbcan.2025.189341

BibTeX
@article{Liu2025,
  author = {Liu, Qi and Song, Mingyuan and Wang, Yan and Zhang, Ping and Zhang, Hao},
  title = {CCL20-CCR6 signaling in tumor microenvironment: Functional roles, mechanisms, and immunotherapy targeting},
  journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
  year = {2025},
  volume = {1880},
  number = {3},
  pages = {189341},
  doi = {10.1016/j.bbcan.2025.189341}
}
Kostenlos starten →